The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Langanecha Bhavikkumar, Jeewa Aamir, Adachi Iki, Mavroudis Constantine D, Shezad Muhammad, Absi Mohammed, Aljohani Othman, Amdani Shahnawaz, Auerbach Scott, Butts Ryan, Byrnes Jonathan, Castleberry Chesney, Conway Jennifer, Edelson Jonathan B, Joong Anna, Khan Sairah, Kindel Steven, Law Sabrina, Lorts Angela, May Lindsay, Nandi Deipanjan, Parent John Jerry, Philip Joseph, Rosenthal David, Sutcliffe David, Tunuguntla Hari, VanderPluym Christina, Zinn Matthew, O'Connor Matthew J, Hope Kyle
Аннотация
BACKGROUND: Ventricular assist device (VAD) explantation following myocardial functional recovery (MFR) remains rare in both adults and children. We aim to study the characteristics and outcomes of durable VAD explantation following MFR in children from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry.
METHODS: All explants of durable VAD, defined as intracorporeal continuous flow devices (ICF) and paracorporeal pulsatile flow devices (PPF), performed between March 2012 and August 2023 were identified within ACTION. Temporary devices were excluded. The primary outcome was VAD and heart transplant-free survival following explantation.
RESULTS: A total of 31 out of 938 patients (3.3%) underwent durable VAD explantation following MFR after a median VAD support duration of 111 days (IQR 59-183). The median age was 1.17 years (IQR 0.32-10.1), and weight was 8.4 kg (IQR 6-23.8). The underlying diagnosis was dilated cardiomyopathy/myocarditis in 64% (20/31) and congenital heart disease in 10% (3/31); others (8/31) accounted for 26%. Following VAD explantation, 10% (3/29) underwent reimplantation of VAD, 14% (4/29) underwent heart transplantation, and 3.4% (1/29) died following explantation. At the last follow-up, 72% (21/29) are alive without reimplantation of a VAD or heart transplantation at a median duration post-explant of 2 years.
CONCLUSIONS: Myocardial functional recovery resulting in VAD explantation remains a rare occurrence in children. However, the majority of children did not require advanced heart failure therapies after durable VAD explant, suggesting appropriate selection of candidates. Strategies to identify patients who may benefit from explantation and predictors of myocardial functional recovery after VAD are warranted.
METHODS: All explants of durable VAD, defined as intracorporeal continuous flow devices (ICF) and paracorporeal pulsatile flow devices (PPF), performed between March 2012 and August 2023 were identified within ACTION. Temporary devices were excluded. The primary outcome was VAD and heart transplant-free survival following explantation.
RESULTS: A total of 31 out of 938 patients (3.3%) underwent durable VAD explantation following MFR after a median VAD support duration of 111 days (IQR 59-183). The median age was 1.17 years (IQR 0.32-10.1), and weight was 8.4 kg (IQR 6-23.8). The underlying diagnosis was dilated cardiomyopathy/myocarditis in 64% (20/31) and congenital heart disease in 10% (3/31); others (8/31) accounted for 26%. Following VAD explantation, 10% (3/29) underwent reimplantation of VAD, 14% (4/29) underwent heart transplantation, and 3.4% (1/29) died following explantation. At the last follow-up, 72% (21/29) are alive without reimplantation of a VAD or heart transplantation at a median duration post-explant of 2 years.
CONCLUSIONS: Myocardial functional recovery resulting in VAD explantation remains a rare occurrence in children. However, the majority of children did not require advanced heart failure therapies after durable VAD explant, suggesting appropriate selection of candidates. Strategies to identify patients who may benefit from explantation and predictors of myocardial functional recovery after VAD are warranted.